A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

Shigeto KobayashiDepartment of Internal Medicine, Rheumatology, Juntendo Koshigaya Hospital, Juntendo University School of Medicine, 560 Fukuroyama, Koshigaya, Saitama 343-0032, JapanCorrespondence[email protected]

Masayoshi HarigaiTokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

Neelufar MozaffarianAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA

Aileen L. PanganAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA

Shringi SharmaAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA

L. Steven BrownAbbott, 200 Abbott Park Road, Abbott Park, IL 60064, USA

Nobuyuki MiyasakaTokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

show all

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date